PPAR Agonist Compounds for Bone and Cartilage Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis and osteoarthritis are inadequate, as they only reduce fracture risk by 65% and offer significant risks, while there are no medical treatments to prevent or halt osteoarthritis progression, leading to significant morbidity and mortality.
Innovation Solution
A method involving the use of PPARδ agonists and 20-OH-PGE2 antagonists to induce osteogenesis or chondrogenesis in mammalian stem cells, promoting bone or cartilage formation, which can be administered through various routes including surgical implantation, injection, or delivery systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medications are used to treat osteoporosis, then fracture risk is reduced by 65%, but significant risks occur including avascular necrosis, subtrochanteric femur fractures, and malignant bone tumors
Solution Approach 1:
The patent extracts and isolates specific PPARγ agonist compounds from the class of bisphosphonate medications, identifying a subset of compounds that achieve fracture risk reduction without the harmful side effects. This involves selecting specific chemical structures with particular substituents that confer selective efficacy and safety profiles.
Solution Approach 2:
The patent modifies chemical parameters of PPARγ agonist compounds by varying substituents at specific positions (R1-R6) to optimize the balance between therapeutic efficacy and safety. By changing molecular structure parameters, the compounds achieve selective activation of PPARγ without triggering the adverse effects associated with conventional bisphosphonates.
2Reliability
If no medical treatments are available for osteoarthritis, then progression cannot be prevented or halted, but this leads to crippling joint pain and deformity
Solution Approach 1:
The patent employs PPARγ agonist compounds as intermediary substances that mediate the protective effect against osteoarthritis progression. These compounds act as molecular mediators that activate PPARγ receptors in cartilage and joint tissues, triggering protective biological responses that prevent disease progression and reduce pain and deformity.
3Ease of operation
If standard of care for osteoarthritis uses supportive pain management measures, then patient comfort is maintained temporarily, but the disease progression continues until joint fusion or replacement is required
Solution Approach 1:
The patent implements preliminary protective action by administering PPARγ agonist compounds that prevent osteoarthritis progression before it reaches the stage requiring joint fusion or replacement. This proactive approach extends the duration of natural joint function and delays or prevents the need for surgical intervention.
Data Source
AI summary
Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.